The mammalian Target of Rapamycin (mTOR) is an evolutionarily conserved member of the phosphatidylinositol-3-OH (PI-3)-kinase-related kinase (PI3KK) family that plays a central role in the regulation of metabolism, protein synthesis, energy balance, proliferation and survival [@R1]. mTOR senses environmental cues such as amino acids, insulin, and growth factors and then integrates these signals in order to regulate cellular metabolism [@R2]. mTOR forms the core of two distinct signaling complexes whose activation is differentially regulated [@R3], [@R4]. mTOR complex 1 (mTORC1) contains the scaffolding protein regulatory-associated protein of mTOR (Raptor) as well as mlST8 (mammalian lethal with Sec13 protein 8), PRAS40 (the proline-rich Akt substrate 40 kDa) and DEP-domain-containing mTOR-interacting protein (Deptor) [@R5]. Activation of mTORC1 is achieved through the PI-3K, PDK1, Akt signaling. mTORC1 promotes the phosphorylation of the translational regulators S6K1 and 4E-BP1 and is believed to play a central role in regulating cellular growth and proliferation by modulating metabolism [@R6]. The second mTOR signaling complex (mTORC2) consists of mlST8, the scaffolding protein raptor-independent companion of TOR (Rictor), mSIN1 proteins, and the protein observed with Rictor (Protor) [@R5]. Rictor is a critical adaptor protein for mTORC2 and Rictor-deficient mice and MEFs have been shown to lack mTORC2 activity [@R4]. mTORC2 activity can be measured by the hydrophobic motif phosphorylation of Akt on serine 473 and other AGC kinases (SGK1 and PKCα) [@R7]. The exact upstream activators of mTORC2 signaling have yet to be fully elucidated. Despite ongoing studies delineating both upstream activators and downstream effectors of the two respective signaling pathways, distinct physiological consequences mediated by mTORC1 and mTORC2 have yet to be defined in biologic systems.

A central role for mTOR in sensing the immune microenvironment and dictating immune function and differentiation has begun to emerge[@R8]. CD4^+^ T cells lacking mTOR fail to differentiate into effector cells under appropriate skewing conditions [@R9]. Instead, upon activation, the mTOR-deficient T cells become Foxp3^+^ regulatory cells. This inability to differentiate into effector cells in the absence of mTOR was associated with a decrease in the activation of the STAT4, STAT6 and STAT3 transcription factors in response to the skewing cytokines interleukin 12 (IL-12), IL-4 and IL-6 respectively. mTOR controls CD8^+^ memory T cell development in part by regulating the expression of the transcription factors T-bet and Eomesodermin[@R10], [@R11]. In addition, the PI-3K-mTOR axis regulates lymphocyte trafficking[@R12]

The Ras Homologue Enriched in Brain (Rheb) is a small GTPase isolated from the central nervous system, and originally thought to be a mediator of the Ras-MAPK pathway[@R13], [@R14]. The mammalian Rheb family consists of two proteins, Rheb1 and Rheb2, both of which are expressed in T cells but their function has yet to be elucidated[@R13], [@R15]. Rheb is a crucial regulator of mTORC1 signaling[@R16]. The tuberous sclerosis complex (TSC, which is comprised of TSC1 and TSC2) functions as a GTPase-activating protein (GAP) for Rheb. When TSC is inhibited, the active, GTP-bound form of Rheb interacts with mTORC1 to stimulate its activity[@R15].

Despite the emerging appreciation for the central role of mTOR in regulating T cell effector, memory and regulatory cell differentiation, the downstream signaling pathways involved in regulating these processes have yet to be elucidated. By selectively knocking out Rheb in T cells we demonstrate that both T~H~1 and T~H~17 effector differentiation require mTORC1 signaling, while T~H~2 differentiation is preserved. Mice which harbor T cell-specific deletions of Rheb cannot mount T~H~1 and T~H~17 responses *in vivo* and are resistant to the development of classical experimental autoimmune encephalomyelitis (EAE). Since T cells lacking mTORC1 activity were still able to become T~H~2 cells, we further investigated the role of mTORC2 signaling on T~H~2 development. By deleting mTORC2 signaling in T cells we found that they were unable to become T~H~2 cells but maintained their ability to differentiate into T~H~1 and T~H~17 cells. Our findings define distinct downstream signaling pathways as the mechanism by which mTOR regulates T helper cell differentiation.

RESULTS {#S1}
=======

Rheb regulates mTORC1 activity in T cells {#S2}
-----------------------------------------

We hypothesized that genetic deletion of Rheb in T cells would inhibit mTORC1 activation. As such, Rheb floxed mice were bred to CD4-Cre mice leading to the deletion of Rheb from T cells ([Supplementary Fig. 1](#SD1){ref-type="supplementary-material"}). CD4^+^ T cells from wild-type and T-*Rheb*^−/−^ mice were stimulated with anti-CD3+ anti-CD28 and interrogated biochemically for mTORC1 and mTORC2 activity. Upon stimulation, wild-type T cells markedly phosphorylate S6K1, indicative of mTORC1 activity ([Fig. 1a, b](#F1){ref-type="fig"}). In contrast, S6K1 phosphorylation was virtually absent from the activated T-*Rheb*^−/−^ T cells. Phosphorylation of Akt at threonine 308 (which is PDK1-dependent and upstream of mTORC1) remained intact in the T-*Rheb*^−/−^ T cells ([Fig. 1a, b](#F1){ref-type="fig"}). Likewise, phosphorylation of Akt at serine 473 (which is downstream of mTORC2) remained intact.

Next we sought to determine the functional consequences of deleting Rheb in T cells. The percentages of CD8^+^, CD4^+^ T cells and B cells were similar between the wild-type and T-*Rheb*^−/−^ mice ([Fig. 1c](#F1){ref-type="fig"} and [Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}). In addition, in spite of the lack of mTORC1 activity, we did not see any differences in the development of Foxp3^+^ T cells. Similar to T cells lacking mTOR[@R9], T cells from the T-*Rheb*^−/−^ mice did not demonstrate a block in proliferation but rather proliferated slower than their wild-type counterparts ([Fig. 1d](#F1){ref-type="fig"}). Likewise, IL-2 production was similar between the wild-type and T-*Rheb*^−/−^ T cells indicating that TCR-induced activation and subsequent expression of IL-2 was not impacted by the absence of Rheb ([Fig. 1e](#F1){ref-type="fig"}). In some systems, mTOR signaling can affect apoptosis. Upon *in vitro* activation, there was no evidence for increased apoptosis by Annexin V and 7-AAD staining in T cells from the T-*Rheb*^−/−^ mice ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). Thus, deleting Rheb in T cells specifically eliminates mTORC1 activity while preserving mTORC2 activity. Furthermore, elimination of Rheb in T cells still permits TCR-induced cytokine expression and proliferation.

T~H~1 and T~H~17 but not T~H~2 differentiation require mTORC1 {#S3}
-------------------------------------------------------------

In light of the fact that mTOR-deficient T cells fail to differentiate into T~H~1, T~H~2 or T~H~17 effector cells, we wanted to determine the effect of Rheb deletion on T cell differentiation. There was no difference in naïve and memory T cell compartments from wild-type and T-*Rheb*^−/−^ littermates, as assayed using freshly-isolated lymphocytes ([Supplementary Fig. 4](#SD1){ref-type="supplementary-material"}). Similar to T cells lacking mTOR, T-*Rheb*^−/−^ T cells failed to differentiate into T~H~1 cells under appropriate skewing conditions *in vitro* ([Fig. 2a](#F2){ref-type="fig"}). T-*Rheb*^−/−^ T cells also failed to differentiate into T~H~17 cells ([Fig. 2b](#F2){ref-type="fig"}). These observations identify mTORC1 signaling as being the downstream mediator of mTOR-dependent T~H~1 and T~H~17 differentiation. In marked contrast to mTOR-deficient T cells, the T-*Rheb*^−/−^ T cells were capable of differentiating into T~H~2 cells ([Fig. 2c](#F2){ref-type="fig"}). Therefore, the inhibition of mTORC1 activity by the deletion of Rheb selectively inhibited T~H~1 and T~H~17 differentiation but preserved T~H~2 differentiation.

To examine if the defect in T~H~1 skewing was linked to the proliferative defect in the Rheb-deficient T cells, we labeled wild-type and Rheb-deficient T cells with CFSE, cultured them in T~H~1 and T~H~2 skewing conditions and interrogated them for cytokine production upon rechallenge. Rheb-deficient T cells did proliferate *in vitro*, although at slower rates. Furthermore, Rheb-deficient T cells that divided several times under T~H~1 skewing conditions still could not make interferon (IFN)-γ in amounts comparable to wild-type cells ([Fig. 2d](#F2){ref-type="fig"}). Further, the slightly increased IL-4 production observed did not directly correlate with the number of cell divisions. Thus, the inability of Rheb-deficient T cells to differentiate into T~H~1 cells was not secondary to their slower rate of proliferation.

Next we sought to confirm these results *in vivo*. Vaccinia virus infection leads to a robust T~H~1 response. T cells from wild-type and T-*Rheb*^−/−^ mice crossed onto the OT-II TCR transgenic background specific for ovalbumin (OVA) were adoptively transferred into wild-type C57/BL6 mice[@R17]. Recipient mice were infected with Vaccinia virus expressing ovalbumin (Vaccinia*-*OVA) and clonotypic T cells were evaluated 5 days later for the expression of IFN-γ and IL-4. As expected, the wild-type OT-II cells differentiated into T~H~1 cells producing robust levels of IFN-γ IL- 2 and TNF-α but little IL-4 ([Fig. 3a, b](#F3){ref-type="fig"}). In marked contrast, T-*Rheb*^−/−^ clonotypic T cells failed to produce robust IFN-γ, but produced significant levels of IL-4. To assess the role of proliferation in this *in vivo* system, OT-II cells were labeled with CFSE. Cells transferred into non-virus-infected host mice failed to proliferate or produce cytokines upon rechallenge, while wild-type T cells transferred into immunized mice proliferated *in vivo* and produced IFN-γ ([Fig. 3c](#F3){ref-type="fig"}). However, Rheb-deficient T cells, even in the case of cells undergoing multiple rounds of proliferation fail to produce IFN-γ. Addition of an IL-4 neutralizing antibody to the culture conditions failed to rescue IFN-γ production (data not shown). These data demonstrate that selective deletion of mTORC1 signaling leads to enhanced T~H~2 differentiation. Thus, selective inactivation of mTORC1 in T cells did not lead to T cell tolerance, but rather promoted differentiation down an alternative effector pathway.

The ability of Rheb-deficient T cells to differentiate into T~H~17 cells *in vivo* was also determined. T~H~17 cells develop *in vivo* in the gut in response to pathogens. Following a brief PMA and Ionomycin stimulation *in vitro*, there was a marked decrease in *in vivo* differentiated CD3^+^CD4^+^ T~H~17 in the Peyer's Patch in T-*Rheb*^−/−^ mice compared to wild-type ([Fig. 3d](#F3){ref-type="fig"}). Overall, these data show that T~H~1 and T~H~17 but not T~H~2 differentiation is specifically regulated by mTORC1 signaling *in vivo* and *in vitro*.

T-Rheb^−/−^ mice are resistant to EAE {#S4}
-------------------------------------

Because both T~H~1 and T~H~17 T cells are implicated in promoting autoimmune diseases and IFN-γ and IL-17 participate in promoting the pathology seen in EAE, we determined the susceptibility of the T-*Rheb*^−/−^ mice to this experimental model [@R18]. Following MOG~35--55~ peptide immunization, wild-type mice developed clinical EAE ([Fig. 4a](#F4){ref-type="fig"}) while T-*Rheb*^−/−^ mice had decreased clinical scores, associated with decreased leukocytic infiltration in the spinal cord and the decreased expansion of T~H~1 and T~H~17 cells ([Fig. 4b, c](#F4){ref-type="fig"}). However, nearly 60% (on average) of MOG-immunized T-*Rheb*^−/−^ mice developed "non-classical EAE" ([Supplementary Video 1](#SD1){ref-type="supplementary-material"}), which is characteristic of T~H~2 responses to MOG ([Fig. 4d](#F4){ref-type="fig"}). MOG-specific T~H~2 cells or IFN-γ^−/−^ cells can induce a neurologic disorder characterized by ataxia (not paralysis) and infiltration of the cerebellum with immune cells [@R19]. T-*Rheb*^−/−^ mice displayed increased leukocytic infiltration, including CD4 cells, in the cerebellum, ([Fig. 4e](#F4){ref-type="fig"}) and T cells isolated from these mice produced increased levels of IL-4 and IL-5 in response to MOG peptide *in vitro* (data not shown). Thus, the mTORC1-deficient T cells were neither "immunodeficient" nor incapable of trafficking to the CNS. Thus, the selective deletion of mTORC1 signaling leads to enhanced T~H~2 differentiation *in vivo*, even under strongly T~H~1/T~H~17 promoting conditions.

T~H~2 but not T~H~1 or T~H~17 differentiation requires mTORC2 signaling {#S5}
-----------------------------------------------------------------------

We further bred Rictor floxed mice to CD4-Cre mice to determine the effect of selectively eliminating mTORC2 in T cells (*T-Rictor*^−/−^, [Supplementary Fig. 5](#SD1){ref-type="supplementary-material"})[@R20]. Following anti-CD3 + anti-CD28 stimulation, T*-Rictor*^−/−^ T cells manifested a decrease in mTORC2 activity as determined by Akt hydrophobic motif (serine 473) phosphorylation. mTORC1 activity in these cells, as determined by the phosphorylation of S6K1, was normal ([Fig. 5a, b](#F5){ref-type="fig"}). In agreement with observations made in Rictor-deficient mice[@R7], proximal (PI3K-PDK1) signaling, assayed by Akt phosphorylation at threonine 308, was intact and consistently higher. T*-Rictor*^−/−^ CD4 T cells developed normally (a slight decrease in the percentage of peripheral CD8s was observed) ([Supplementary Fig. 6](#SD1){ref-type="supplementary-material"}) and produced equivalent amounts of IL-2 ([Supplemental Fig. 7](#SD1){ref-type="supplementary-material"}) as the wild-type T cells indicating that TCR-induced signaling was intact. *Rictor*^−/−^ T cells displayed slower proliferation upon stimulation, but had a less severe defect than *Rheb^−/−^* T cells ([Supplementary Fig. 7](#SD1){ref-type="supplementary-material"}). In addition, T-*Rictor*^−/−^ mice did not demonstrate an increase in activation-induced apoptosis ([Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}) and have normal proportions of CD4^+^ T cells in the naïve compartment ([Supplementary Fig. 8](#SD1){ref-type="supplementary-material"}).

*T-Rictor*^−/−^ T cells were able to develop into T~H~1 and T~H~17 T cells under appropriate skewing conditions *in vitro* ([Fig. 5c, d](#F5){ref-type="fig"}), but failed to differentiate down a T~H~2 pathway ([Fig. 5E](#F5){ref-type="fig"}).

To exclude that the presence of previously activated cells may alter skewing conditions in our system, we sorted naïve (CD62L^hi^CD44^lo^) CD4^+^ cells from wild-type, *T-Rheb*^−/−^, and T-*Rictor*^−/−^ mice and skewed them using plate-bound anti-CD3 and soluble anti-CD28. As seen with bulk CD4^+^ T cells, Rheb-deficient cells fail to differentiate into T~H~1 or T~H~17 cells, and Rictor-deficient cells fail to differentiate into T~H~2 cells ([Supplementary Fig. 9](#SD1){ref-type="supplementary-material"}). TCR signaling strength can affect T~H~1 and T~H~2 responses [@R21]. Specifically, low concentrations of peptide can impair IFN-γ production, and create a bias toward a T~H~2 response To determine the impact of strength of peptide signaling in the differentiation of Rheb- and Rictor-deficient T cells, wild-type, Rheb-, and Rictor-deficient OT-II T cells were stimulated under conditions of widely varying doses of OVA peptide as previously described[@R22]. However, even at a dose of 100μM of peptide, there was no evidence of increased IFN-γ production from Rheb-deficient T cells ([Supplementary Fig. 10](#SD1){ref-type="supplementary-material"}). Alternatively, Rictor-deficient T cells produced T~H~1 cytokines even at exceedingly low doses of peptide.

Consistent with the *in vitro* data, *T-Rictor*^−/−^ T cells produced robust levels of IFN-γ in response to Vaccinia infection ([Fig. 5f](#F5){ref-type="fig"}). T-*Rictor*^−/−^ mice had normal susceptibility to EAE ([Supplementary Fig. 11](#SD1){ref-type="supplementary-material"}), associated with equivalent numbers of IFN-γ and IL-17 producing cells in response to MOG peptide as the wild-type. To assess T~H~2 responses *in vivo*, wild-type (C57/BL6), T-*Rheb*^−/−^ and T*-Rictor*^−/−^ mice were primed and boosted with OVA using alum as an adjuvant to elicit a T~H~2 response. Compared with wild-type and T-*Rheb*^−/−^ mice, T*-Rictor*^−/−^ mice had reduced induction of IL-4-secreting OVA specific T cells ([Fig. 5g](#F5){ref-type="fig"}) and failed to generate antigen-specific IgG1 antibodies (that are dependent upon T~H~2 cell help) ([Fig. 5h](#F5){ref-type="fig"}). Thus, mTORC2 regulates the ability of helper T cell to differentiate toward T~H~2 cells.

Distinct STAT activation by mTORC1 and mTORC2 {#S6}
---------------------------------------------

Next we determined if we could reproduce these results in wild-type primary T cells using pharmacological inhibition of mTOR activity. Biochemical analysis of T cells revealed that rapamycin can inhibit mTORC2 activity ([Fig. 6a](#F6){ref-type="fig"})[@R23]. However, at very low doses (100--500pM, referred to as VLD) rapamycin selectively inhibits mTORC1 in T cells. VLD of rapamycin specifically inhibited T~H~1 differentiation in naïve wild-type T cells activated under either T~H~1 or T~H~2 skewing conditions ([Fig. 6B](#F6){ref-type="fig"}), consistent with the findings in Rheb-deficient T cells.

It is known that T cells lacking mTOR cannot differentiate into effector cells, due in part to diminished responses to T helper skewing cytokines[@R9]. Freshly isolated T cells from wild-type, T-*Rheb*^−/−^ and T *Rictor*^−/−^ mice were exposed to skewing cytokines and STAT activation was assessed. Consistent with their inability to become T~H~1 and T~H~17 cells, T-*Rheb*^−/−^ T cells showed decreased STAT4 and STAT3 phosphorylation in response to IL-12 and IL-6 respectively ([Fig. 6c](#F6){ref-type="fig"}, left panel). However, T-*Rheb*^−/−^ T cells demonstrated enhanced STAT6 phosphorylation in response to IL-4 (a T~H~2-promoting cytokine). T-*Rictor*^−/−^ T cells showed intact IL-12 and IL-6-induced STAT4 and STAT3 activation, while IL-4-induced STAT6 activation was diminished ([Fig. 6C](#F6){ref-type="fig"}, right panel). These findings indicate that the ability of mTORC1 and mTORC2 to differentially regulate T cell effector differentiation is due in part to their ability to differentially regulate STAT activation. In response to different cytokines, Rheb-deficient T cells showed decreased IL-23- and IFN-β--induced STAT4 activation and decreased IL-10- and IL-21-dependent STAT3 activation (data not shown). Rictor-deficient T cells showed decreased STAT6 activation in response to IL-13 (data not shown).

mTOR was previously shown to influence STAT activation[@R9], [@R24], [@R25]. To determine how distinct STATs are differentially regulated in T cells, we examined cytokine receptor expression on Rheb- and Rictor-deficient T cells. IL-12Rβ1, IL-4R and IL-6R were all expressed at equivalent levels in the wild-type, Rheb and Rictor-deficient T cells, indicating that mTOR did not regulate cytokine receptor expression ([Supplementary Fig. 12](#SD1){ref-type="supplementary-material"}).

STAT activation is partially regulated by the expression of SOCS (Suppressor Of Cytokine Signaling) proteins, which can differentially dephosphorylate JAK-dependent residues on STAT proteins. We determined the expression pattern of SOCS3 and SOCS5 in the Rheb and Rictor-deficient T cells. Consistent with previously published findings, wild-type T cells expressed SOCS3 (mRNA and protein) at baseline and downregulated its expression upon activation[@R26]--[@R28] ([Fig. 6d, e](#F6){ref-type="fig"}) while SOCS5 expression was low in naïve T cells and increased with activation[@R29], [@R30]. In resting Rheb-deficient T cells SOCS3 mRNA and protein expression was markedly increased, and retained higher expression upon activation ([Fig. 6d, e](#F6){ref-type="fig"}), while SOCS5 expression was similar to wild-type cells. Rictor-deficient T cells displayed SOCS3 at baseline (albeit lower amounts than the wild-type cells) and this expression decreased upon activation, while SOCS5 expression was markedly upregulated in the resting cells and remained elevated upon activation ([Fig. 6d, e](#F6){ref-type="fig"}). Thus, at baseline and upon activation, the levels of SOCS3 and SOCS5 are differentially regulated in the Rheb-deficient and Rictor-deficient T cells.

SOCS protein expression is dynamically regulated over time. To examine the expression patterns of SOCS proteins at later time points, T cells were activated for 48, 72, and 96 h. At these time points, SOCS3 protein remained elevated in Rheb-deficient T cells, while wild-type and Rictor-deficient cells downregulated SOCS3 ([Fig. 6f](#F6){ref-type="fig"}). Further, while wild-type and Rheb-deficient cells consistently upregulated SOCS5 upon activation, Rictor-deficient T cells displayed significantly elevated levels of SOCS5 at later time points.

To prove that the increased levels of SOCS3 in the Rheb-deficient T cells and the increased levels of SOCS5 in the Rictor-deficient T cells had functional significance, we transfected freshly isolated wild-type, Rheb-, and Rictor-deficient CD4^+^ T cells with siRNA against SOCS3 and SOCS5. This resulted in significant knockdown of SOCS3 and SOCS5 mRNA ([Supplementary Fig. 13](#SD1){ref-type="supplementary-material"}). In T cells stimulated in T~H~1 and T~H~2 differentiation conditions knockdown of SOCS3 mRNA resulted in increased IFN-γ production in Rheb-deficient T cells ([Fig. 6g](#F6){ref-type="fig"}), while knock down of SOCS5 mRNA in Rictor-deficient T cells resulted in increased ability to produce IL-4 ([Fig. 6h](#F6){ref-type="fig"}). Such observations demonstrate that SOCS proteins regulated T~H~1, T~H~17 and T~H~2 differentiation in the Rheb- and Rictor-deficient T cells.

Transcription factor expression in T-Rheb^−/−^ and T-Rictor^−/−^ T cells {#S7}
------------------------------------------------------------------------

Next we sought to determine if the transcription factors T-bet, RORγT and GATA-3, which play critical roles in the development of T~H~1, T~H~17 and T~H~2 cells are selectively affected by Rheb or Rictor deletion. Rheb-deficient T cells failed to fully upregulate T-bet message and protein under T~H~1 conditions ([Fig. 7a, b](#F7){ref-type="fig"}) and RORγT under T~H~17 conditions, while strongly expressing GATA-3 under T~H~2 conditions. In fact, GATA-3 was expressed at higher levels in Rheb-deficient cells than in wild-type cells, consistent with their enhanced ability to phosphorylate STAT6 and produce IL-4 *in vivo*. In *Rictor*^−/−^ T cells, both T-bet and RORγT were transcribed and translated under T~H~1 and T~H~17 conditions respectively, but GATA-3 failed to be expressed under T~H~2 conditions ([Fig. 7a and b](#F7){ref-type="fig"}). In T cells stimulated in T~H~1 and T~H~2 differentiation conditions, knockdown of SOCS3 mRNA resulted in increased in T-bet expression in Rheb-deficient T cells ([Fig. 7c](#F7){ref-type="fig"}), while knock down of SOCS5 mRNA in Rictor-deficient T cells resulted in increased GATA-3 expression ([Fig. 7c](#F7){ref-type="fig"}). Furthermore, wild-type T cells exposed to VLD rapamycin (which inhibits T~H~1 but not T~H~2 development) demonstrated decreased T-bet expression but not decreased GATA3 expression in response to the appropriately differentiating conditions ([Fig. 7d](#F7){ref-type="fig"}). Thus, in the absence of the nutrient sensitive signaling pathways mediated by mTOR, the ability to respond to cytokines is diminished, and T cells fail to properly upregulate lineage-specific transcription factors.

Treg development in the absence of mTORC1 and mTORC2 {#S8}
----------------------------------------------------

It is known that mTOR deficient T cells differentiate down a Foxp3^+^ T regulatory pathway and that inhibition of mTORC1 alone is not sufficient for the generation of Tregs [@R9]. Rapamycin can enhance the generation of inducible regulatory T cells [@R31]--[@R33]. To determine the specific effect of mTORC1 and mTORC2 on regulatory T cell differentiation, wild-type, T-*Rheb*^−/−^, *T-Rictor*^−/−^ and T-*Mtor*^−/−^ T cells were cultured *in vitro* under activating conditions (in the absence of exogenous TGF-β) and then assessed for the generation of Foxp3^+^ T cells. Neither the elimination of mTORC1 nor mTORC2 signaling alone led to an increase in Foxp3+ cells ([Fig. 8a](#F8){ref-type="fig"}). Notably however, inducible regulatory T cells (made with TGF-β and IL-2) from wild-type, T-*Rheb*^−/−^, T*-Rictor*^−/−^ mice all appeared to inhibit T cell function equally ([Fig. 8b](#F8){ref-type="fig"}).

To further test the hypothesis that both mTORC1 and mTORC2 must be inhibited in order to generate regulatory T cells, wild-type, T-*Rheb*^−/−^ and T*-Rictor*^−/−^ T cells were activated in the presence of a conventional dose (500nM, which inhibits mTORC1 and mTORC2) or VLD (500pM, which only inhibits mTORC1) of rapamycin. Wild-type T cells differentiated into Foxp3^+^ T cells at the conventional 500 nM dose that inhibits mTORC1 and mTORC2 ([Fig. 8c](#F8){ref-type="fig"}). T-*Rheb*^−/−^ T cells required mTORC2 inhibition induced by the conventional dose. In contrast, T*-Rictor*^−/−^ T cells require only VLD rapamycin to differentiate into T~reg~s. Finally, a mTOR-specific kinase inhibitor DMK1 (which acutely inhibits both mTOR downstream signaling pathways) [@R34] promoted T~reg~ generation from naïve wild-type T cells, consistent with our data from mTOR-, mTORC1- and mTORC2-deficient T cells ([Fig. 8d](#F8){ref-type="fig"}). Thus, both mTORC1 and mTORC2 inhibition is required for the generation of regulatory T cells in the absence of exogenous TGF-β.

DISCUSSION {#S9}
==========

In this report, we define precise and reciprocal roles for mTORC1 and mTORC2 signaling in regulating CD4^+^ T helper cell differentiation. Our data ascribe tissue distinct physiologic functions of mTORC1 and mTORC2. Thus, mTORC1 signaling promotes T~H~1 and T~H~17 differentiation, mTORC2 signaling promotes T~H~2 differentiation and mTOR inhibition leads to regulatory T cells. Preliminary studies from our lab have failed to demonstrate the differential activation of mTORC1 and mTORC2 under T~H~1 and T~H~2 skewing conditions. As such we hypothesize that it is the differential expression and activation of downstream substrates and signaling pathways that confer the ability of mTORC1 to regulate T~H~1 and T~H~17 differentiation and mTORC2 to regulate T~H~2 differentiation.

Our studies provide a critical link between metabolism and T cell differentiation. mTORC1 signaling integrates growth factors, energy, oxygen and amino acids to promote processes necessary for cell growth [@R2], [@R5]. In addition, in T cells, the PI3K-Akt-mTORC1 axis is activated by CD28 engagement and IL-2 receptor signaling[@R35]. IL-7 promotes mTOR activity, helping to prevent atrophy in T cells, [@R36] while IL-4-induced mTOR activity prevents apoptosis[@R37]. IL-12 and IFN-γ promote the sustained activation of mTORC1 activity in CD8+ T cells.[@R11], [@R38] Relatively little is known about the precise role of mTORC2 signaling in regulating cellular function [@R5]. The ability of mTORC2 to regulate T~H~2 differentiation provides potential clues for determining the specific role of mTORC2 in other cell types.

The small GTPase Rheb was recently identified as an activator of mTORC1[@R15]. Our data demonstrate that Rheb signaling plays an important role in regulating T cell differentiation. mTOR-deficient T cells, Rheb-deficient T cells and T cells treated with very low doses of rapamycin, which only inhibits mTORC1, all inhibit CD4^+^ effector cell differentiation, supporting the hypothesis that the ability of Rheb to direct differentiation is through the activation of mTORC1. Furthermore, mTORC1 signaling appears to be both necessary and sufficient for T~H~1 and T~H~17 differentiation because Rictor-deficient T cells still maintain their ability to become T~H~1 and T~H~17 effectors.

A recent study has examined Rictor-deficient T cells generated by crossing Lck-Cre and floxed Rictor mice [@R39]. Consistent with our study, Rictor deletion inhibited T~H~2 differentiation. However, a decrease in the generation of T~H~1 cells (albeit modest compared to T~H~2 inhibition) was also reported. The cause of these divergent observations remains unclear. The use of Lck-Cre can lead to subtle differences in T cell development and affect T~H~ differentiation. Additionally, we found that under T~H~1 conditions, Rictor-deficient T cells can generate greater T~H~17 cells than normal. In addition, there appear to be differences in signaling between the Rictor deficient T cells employed in each study. Notably, unlike our mice, which demonstrate robust phosphorylation of Akt threonine 308 and subsequent S6K1 activation, T cells in this other study show decreased signaling *upstream* of mTOR[@R39], which could also impair mTORC1 signaling. We suggest that when the signaling defects are restricted downstream of mTORC2 signaling, there is a selective block in T~H~2 but not T~H~1 development. Thus, it is possible that Rictor-deficient T cells in the abovementioned report behave more like mTOR-deficient T cells.

Rapamycin promotes the generation of regulatory T cells in the absence of exogenous TGF-β[@R40]--[@R42]. PD-L1 was shown to promote inducible regulatory T cells by inhibiting mTOR activation[@R43]. In addition, local depletion of essential amino acids can promote the generation of regulatory T cells by inhibiting mTOR activity[@R44]. We show here that both mTORC1 and mTORC2 signaling must be inhibited in order to skew cells down the regulatory T cell pathway. Our genetic studies were complemented by a pharmacologic approach. The simultaneous inhibition of mTORC1 and mTORC2 by an mTOR kinase inhibitor was a potent inducer of regulatory T cells in the absence of exogenous TGF-β indicating that this class of drugs can act as potent immunosuppressive/tolerance-inducing agents.

mTORC1 and mTORC2 can promote cell differentiation in other tissues. Cerebral cortical development is mTORC1 dependent while terminal differentiation of myoblasts is mTORC2 mediated[@R45], [@R46]. In this model, mTORC2 signaling inactivates Rho-associated kinase ROCK1, which in turn promotes the activation of the transcription factors FoxO1 and FoxO3a. We demonstrate a similar role for mTORC1 and mTORC2 signaling in regulating distinct tissue specific transcription factors. It was recently shown that rapamycin promotes CD8^+^ memory cell differentiation[@R10]. Thus, by inhibiting T-bet expression, rapamycin not only inhibits effector functions (such as IFN-γ production) but promotes the expression of Eomesodermin which in turn promotes the generation of memory T cells[@R11]. The decrease in T~H~ specific transcription factors is due to a decrease in specific STAT activation in response to cytokines. While the IL-12-, IL-6- and IL-4-induced STAT4, STAT3 and STAT6 phosphorylation is not completely lost in the mTORC1-and mTORC2-deficient T cells, the decreased response contributes to the observed differentiation failure. The ability of mTOR to regulate STAT3 phosphorylation was described in cancer and neuron activation however, the precise mechanism for this regulation is unclear [@R24], [@R25], [@R47]. In T cells we show that differences in SOCS3 and SOCS5 expression contribute to the STAT activation defects. Along these lines, mTORC2 inhibits the activity of Foxo transcription factors[@R7], [@R48]. Foxos control KLF2 expression, which in turn promotes SOCS5 expression[@R49]. Preliminary studies show an increase in KLF2 in Rictor-deficient T cells, consistent with the observed increase in SOCS5 in these cells (data not shown). We propose a model whereby mTORC1 and mTORC2 activate distinct signaling programs the net sum of which is to promote specific effector differentiation. Future studies will seek to identify the mTORC1 and mTORC2 specific targets that control differentiation.
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![Rheb controls mTORC1 activity in T cells. (**a**) Immunoblot (IB) of mTOR activation in lysates from wild-type and T-*Rheb*^−/−^ CD4^+^ T cells stimulated with anti-CD3 and anti-CD28 in serum free media for 1 or 3 h. (**b**) Densitometry analysis across 4 experiments for mTORC1 (p-S6K1), mTORC2 (p-Akt (S473)), and PI3K (p-Akt (T308)) activity (n=4, \* *p* \<.05, \*\* *p* \<.01, \*\*\* *p* \<.001 by Student's t test). (**c**) Flow cytometric analysis of splenocytes harvested from wild-type or T-*Rheb*^−/−^ mice. CD4 vs CD8 plots are gated on CD3^+^, T~reg~ plots are gated CD3^+^CD4^+^. (**d**) Dilution of CFSE in wild- type and T-*Rheb*^−/−^ CD4^+^ T cells stimulated with anti-CD3 and irradiated autologous APCs for 48 or 96h. (**e**) IL-2 production in wild-type and T-*Rheb*^−/−^ CD4^+^ T cells stimulated with anti-CD3 and anti-CD28 overnight Data are representative of at least 3 independent experiments.](nihms270547f1){#F1}

![mTORC1 is required for T~H~1 and T~H~17 differentiation *in vitro*, but is dispensable for T~H~2 differentiation. (**a**) IFN-γ production in wild-type and T-*Rheb*^−/−^ CD4^+^ T cells stimulated with anti-CD3 and APCs in T~H~1 or T~H~2 skewing conditions, expanded 5 d with IL-2, and restimulated *in vitro* with anti-CD3 and anti-CD28. (**b**) IL-17 production in wild-type and T-*Rheb*^−/−^ CD4^+^ T cells stimulated with anti-CD3 and APCs in T~H~1 or T~H~17 skewing conditions, expanded 5 d, then restimulated with anti-CD3 and APCs in the presence of a protein transport inhibitor. (**c**) As in **a**, but for IL-4. (**d**) CFSE dilution and cytokine production of wild-type and T-*Rheb*^−/−^ CD4^+^ T cells labeled and skewed as in **a** and restimulated with anti-CD3 and anti-CD28 in the presence of a protein transport inhibitor. Data are representative of at least 3 independent experiments.](nihms270547f2){#F2}

![mTORC1-deficient T cells cannot skew to T~H~1 or T~H~17 *in vivo*. (**a**) Cytokine production in C57/BL6 (Thy-1.2^+^) mice that were immunized with Vaccinia*-*OVA and received an adoptive transfer of 1 × 10^6^ wild-type or T-*Rheb*^−/−^ CD4^+^ OT-II T cells (Thy-1.1^+^). Splenocytes were harvested 4 days after transfer and rechallenged overnight *in vitro* with OVA peptide in the presence of a protein transport inhibitor. Plots are gated on Thy-1.1^+^ cells. (**b**) Tabulated results from one independent experiment as in **a**. (n=3, *p* \< .01 for IFN-γ, *p* \< .05 for IL-4, by Student's t test). (**c**) As in **a**, but some mice received a mock immunization, and adoptively transferred cells were CFSE-labeled. (**d**) Cytokine production from Peyer's Patch Lymphocytes (PPL) isolated from wild-type and T-*Rheb*^−/−^ mice and stimulated with PMA and ionomycin (n = 6, \*\* *p* \<.01). Data are representative of at least 3 independent experiments.](nihms270547f3){#F3}

![T-*Rheb*^−/−^ mice do not develop EAE, but instead develop an alternative autoimmune disease. (**a**) Disease progression of wild-type and T-*Rheb*^−/−^ mice immunized with MOG and CFA to induce EAE (n=7, \*\*, *p* \< 0.01 by one-way ANOVA). (**b**) Immunohistochemistry (IHC) for CD45 and CD4 of CNS sections frozen at the height of disease in wild-type mice. (**c**) Cytokine production of CNS samples rested in unsupplemented media for 16 h and stimulated with PMA and ionomycin in the presence of a protein transport inhibitor (n = 4, *p* values indicated are from Student's t test). Plots are gated by CD4 expression and side scatter. (**d**) Incidence of classical or nonclassical EAE in our system. (**e**) As in b, but sections of cerebellum are shown. Data are representative of 3 independent experiments.](nihms270547f4){#F4}

![mTORC2-deficient T cells cannot skew to T~H~2, but retain T~H~1 and T~H~17 skewing. (**a**) IB of mTOR activation in lysates from wild-type and T-*Rictor*^−/−^ CD4^+^ T cells stimulated with anti-CD3 and anti-CD28 in serum free media for 1 or 3 h. (**b**) Densitometry analysis across 4 experiments for mTORC1 (p-S6K1), mTORC2 (p-Akt (S473)), and PI3K (p-Akt (T308)) activity (n=4, \* \<.05, \*\* \<.01, \*\*\* \<.001 by Student's t test). (**c**) IFN-γ production in wild-type, T-*Rheb*^−/−^, and T-*Rictor*^−/−^ CD4^+^ T cells stimulated with anti-CD3 and APCs overnight in T~H~1 or T~H~2 skewing conditions, expanded 5 d with IL-2, and restimulated *in vitro* with anti-CD3 and anti-CD28. (**d**) IL-17 production of wild-type and T-*Rictor*^−/−^ CD4^+^ T cells stimulated with anti-CD3 and APCs in T~H~1 or T~H~17 skewing conditions, expanded 5 d, and restimulated with anti-CD3 and APCs in the presence of a protein transport inhibitor. (**e**) As in **c**, but for IL-4. (**f**) Cytokine production as in **3a**, but some host mice received an adoptive transfer of T-*Rictor*^−/−^ CD4^+^ T cells. (**g**) IL-4 production in CD4^+^ T cells from wild-type, T-*Rheb*^−/−^, and T-*Rictor*^−/−^ mice immunized with alum or ovalbumin with alum and boosted after 14 days. Splenocytes were stimulated 48 h with 100 μg/ml OVA protein (protein transport inhibitor present for the last 8 h). (**h**) OVA-specific serum antibody titers from mice in **g**. Data are representative of at least 3 independent experiments, except for **f**, which was performed twice.](nihms270547f5){#F5}

![mTORC1 and mTORC2 influence cytokine signaling through differential inhibition of SOCS proteins. (**a**) IB of mTOR activation in lysates from wild-type, naive T cells stimulated with anti-CD3 and anti-CD28 in varying doses of rapamycin for 8 h in serum-containing media. (**b**) Cytokine production of wild-type, 5C.C7 T cells stimulated with PCC peptide for 48 h in T~H~1 or T~H~2 skewing conditions in the presence or absence of very low dose (VLD, 100pM) rapamycin, washed and expanded in fresh drug and IL-2 for 5 days, then restimulated with anti-CD3 and anti-CD28. (**c**) IB of STAT phosphorylation in lysates from freshly isolated wild-type, T-*Rheb*^−/−^ and T-*Rictor^−/−^* CD4^+^ T cells resuspended in serum-free media for 1 h and stimulated with IL-12, IL-4, or IL-6 for 30 min. (**d**) SOCS3 and SOCS5 mRNA levels from wild-type, T-*Rheb*^−/−^ and T-*Rictor^−/−^* CD4^+^ T cells stimulated with mock or anti-CD3 and anti-CD28 simulation overnight. Values are normalized to 18s rRNA and scaled to wild-type unstimulated (for SOCS3) or stimulated (for SOCS5). (**e**) IB of SOCS3 and SOCS5 of cells treated as in **d**. (**f**) Kinetic analysis of SOCS3 and SOCS5 protein expression in lysates from wild-type, T-*Rheb*^−/−^ and T-*Rictor^−/−^* CD4^+^ T stimulated with anti-CD3 and anti-CD28 for the indicated times. Actin is included as a loading control. (**g**) IFN-γ production in wild-type, T-*Rheb*^−/−^ and T-*Rictor^−/−^* CD4^+^ T cells transfected with control, SOCS3, and SOCS5 siRNA by nucleofection, rested 16 h, stimulated in T~H~1 and T~H~2 skewing conditions 48 h, then expanded in IL-2 for 48 h and restimulated with anti-CD3 and anti-CD28. (**h**) IL-4 production from cells in **g**. All data are representative of at least three independent experiments, except for **g** and **h**, which were performed twice.](nihms270547f6){#F6}

![Control of transcription factor induction by mTORC1 and mTORC2. (**a**) Lineage-specific transcription factor mRNA expression in wild-type, T-*Rheb*^−/−^ and T-*Rictor^−/−^* CD4^+^ T cells skewed to T~H~1, T~H~2, or T~H~17 as before. ND = not detected. Units are fold over 18S rRNA (for *Tbx21* and *Gata3*) or ddCT arbitrary units (for *Rorc*). (**b**) Flow cytometric analysis of wild-type, T-*Rheb*^−/−^ and T-*Rictor^−/−^* CD4^+^ T cells skewed to T~H~1, T~H~2, or T~H~17 and stained for T-bet, GATA-3, and RORγT. (**c**) Flow cytometric analysis of cells nucleofected as in **6g** and skewed to T~H~1 and T~H~2. The shaded histogram represents wild-type T~H~2 cells (for T-bet) and wild-type T~H~1 cells (for GATA-3). (**d**) Flow cytometric analysis of naive 5C.C7 T cells skewed to T~H~1 or T~H~2 in the presence or absence of VLD rapamycin. All data are representative of at least three independent experiments, except for c, which was performed twice.](nihms270547f7){#F7}

![Inhibition of both mTORC1 and mTORC2 are required for spontaneous T~reg~ induction. (**a**) Foxp3 and CD25 expression in CD4^+^ T cells from wild-type, *T-Rheb^−/−^*, *T-Rictor*^−/−^ and T-*Mtor*^−/−^ mice stimulated with anti-CD3 APCs overnight and rested in IL-7 supplemented media for 5 d. (**b**) CFSE-dilution of wild-type T cells stimulated *in vitro* with anti-CD3 APCs, and varying numbers of Foxp3^+^ T~reg~ generated from wild-type, T-*Rheb*^−/−^, and T-*Rictor*^−/−^ CD4^+^ T cells (using TGF-β and IL- ). T~reg~ were enriched by CD25 magnetic separation, and Foxp3 expression was confirmed by intracellular staining. (**c**) Foxp3 and CD25 expression in wild-type, *T-Rheb*^−/−^, and *T-Rictor*^−/−^ CD4^+^ T cells stimulated with anti-CD3 and APCs in the presence of VLD or conventional dose rapamycin and rested in IL-7 supplemented media (with drug) for 5 days. (**d**) Foxp3 and CD25 expression of wild-type T cells stimulated with anti-CD3 and APCs in the presence or absence of DMK1, a kinase inhibitor of mTOR, and expanded for 5 days in the presence of IL-2 and drug (top panel). IB of mTOR activation in lysates from wild-type T cells stimulated with anti-CD3 and anti-CD28 for 1 or 3 h in serum free media with or without DMK1 (bottom panel). All data are representative of at least 3 independent experiments.](nihms270547f8){#F8}
